UroGen's UGN-103 Phase 3 Trial Achieves 94.5% Six-Month Response Durability, NDA Submission Expected Q3
URGN has more than doubled off its 52-week low of $3.42.
Summary
UroGen Pharma announced highly positive six-month duration of response (DOR) data for UGN-103 from its Phase 3 UTOPIA trial in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC). The trial demonstrated a 94.5% DOR, which is consistent with the pivotal ENVISION trial for their already approved drug, ZUSDURI. This strong data keeps UroGen on track to submit a New Drug Application (NDA) for UGN-103 in the third quarter of 2026, with FDA alignment on the regulatory path. This is a significant step towards expanding UroGen's commercial portfolio and leveraging its proprietary RTGel technology for a second product in a substantial market. Investors will now focus on the upcoming NDA submission and the subsequent regulatory review process.
At the time of this announcement, URGN was trading at $29.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $3.42 to $32.37. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.